5 years from now, Ozempic Could Become the Next Status Symbol
Prescription weight-loss drugs have become one of the biggest health business stories in the U.S. since 2023, when demand for Ozempic, Wegovy, and similar GLP-1 medicines accelerated nationwide. Over the next five years, that trend could push Ozempic further into lifestyle territory, especially in affluent U.S. markets where access, price, and visibility already shape who gets these drugs and when.
Demand and visibility are already setting the stage
Novo Nordisk, the company behind Ozempic and Wegovy, reported in its 2024 annual results that obesity-care sales rose sharply year over year, reflecting demand on a global scale. In the U.S., Ozempic is approved for Type 2 diabetes, while Wegovy is approved for chronic weight management, according to the FDA labels in effect as of 2025. That distinction matters because public attention has often centered on Ozempic by name, even when doctors and patients are discussing the broader GLP-1 category.
By 2025, the visibility gap had become part of the story. Celebrity interviews, red-carpet coverage, and social media posts helped turn one prescription drug name into a household term, even as insurers and pharmacies continued to treat it as a tightly managed medication. IQVIA and company earnings reports have shown sustained U.S. prescription growth in the GLP-1 class, though exact future demand over the next five years is not yet knowable.
What that could look like in local communities
In high-cost metro areas such as New York, Los Angeles, Miami, and Dallas, physicians, med spas, and telehealth companies have already built large businesses around GLP-1 consultations since 2023. What is confirmed today is that access often depends on insurance coverage, pharmacy supply, and monthly out-of-pocket cost, which has exceeded $900 for some patients without coverage, according to list-price reporting and insurer plan documents. What is not yet known is whether those gaps will narrow enough by 2031 to make the drugs routine rather than exclusive.
That local divide is where status signaling could grow. In wealthier ZIP codes, paying cash for branded medication, nutrition coaching, and follow-up care can function as a visible marker of disposable income, much like concierge medicine has in major U.S. cities since the 2010s. Publicly available clinic pricing in 2024 and 2025 showed bundled programs costing hundreds of dollars a month before the drug itself was added.
Why cost, supply, and culture matter most
Several forces are driving this possibility, and each one is grounded in current market conditions. Novo Nordisk and Eli Lilly have both told investors since 2024 that manufacturing expansion is critical because demand has outpaced supply at different points. At the same time, PBM rules, prior authorization requirements, and employer coverage limits have kept access uneven, according to insurer policies and benefits consultants.
Cultural factors matter too. A 2024 KFF Health Tracking Poll found Americans closely divided on the use of prescription weight-loss drugs, showing both high awareness and concerns about affordability and long-term use. For customers over the next five years, that means the label on the pen may continue to signal more than treatment alone, especially if branded supply remains expensive and selective, while broader generic-style affordability is still not in place.
